Tvardi Therapeutics (TVRD) Total Non-Current Liabilities (2023 - 2026)

Tvardi Therapeutics has reported Total Non-Current Liabilities for 4 years, with the latest figure at $11.3 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 843.45% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (up 843.45% YoY) and the FY2025 annual result came in at $11.1 million, up 407.29% from the prior year.
• Total Non-Current Liabilities climbed to $11.3 million in Q1 2026 per TVRD's latest filing, from $11.1 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $31.7 million in Q4 2023 and troughed at -$3.6 million in Q4 2024.
• A 4-year average of $13.1 million and a median of $11.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities plunged 111.43% in 2024, then soared 843.45% in 2026.
• Over 4 years, Total Non-Current Liabilities stood at $31.7 million in 2023, then slumped by 111.43% to -$3.6 million in 2024, then soared by 407.29% to $11.1 million in 2025, then rose by 1.66% to $11.3 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $11.3 million, $11.1 million, and $1.2 million for Q1 2026, Q4 2025, and Q1 2025 respectively.